Jun Qi, Assistant Professor of Medicine at Dana-Farber Cancer Institute, shared a post on LinkedIn:

“It is so exciting to see our collaborative work with Adam Durbin, Ernst Schonbrunn, Martine Roussel, and Brian Abraham to study EP300/CBP bromodomain inhibition in Group 3 medulloblastoma is now published in Nature Communications! It is interesting to see that different type of cancers might rely on EP300/CBP functions very differently. We can use the chemical tool compounds to dissect them out. We are eager to learn more about the pediatric brain tumor and hopefully can find novel therapy for these tough cancers using our chemistry expertise.”

Additional information
Source: Jun Qi/LinkedIn